StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sanofi (SNY) & Regeneron (REGN) Report Dupixent (dupilumab) Showed Positive Phase 3 Results in Adolescents with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis
May 16, 2018 5:50 AM
Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
FDA
Management Comments
Next Articles
Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 1:01 AM
Buffett's Berkshire 13F Confirms Increase in Apple (AAPL) Stake Along with Increase in Holdings of Teva (TEVA) (More...)
May 15, 2018 4:12 PM
